Short answer
COLLEGIUM PHARMACEUTICAL, INC (COLL) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $216M (up 3.3% year over year) with net income of $22M.
Q3 2026 key financials · XBRL
- Revenue
- $216M
- +3.3% YoY · +8.2% QoQ
- Net income
- $22M
- −30.9% YoY · +244.6% QoQ
- Operating margin
- 13.3%
- Gross margin
- 58.0%
- EPS (diluted)
- $0.66
- −21.4% YoY · +257.1% QoQ
Source: XBRL data from the COLLEGIUM PHARMACEUTICAL, INC (COLL) Q3 2026 10-Q on SEC EDGAR. USD.
COLLEGIUM PHARMACEUTICAL, INC Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $216.3M, up $6.9M YoY from $209.4M
- Operating margin 13.3% vs 29.6% YoY, net margin 10.1% vs 15.0%
- Best product: Azstarys revenue $26.5M increase; worst: Nucynta Products revenue $24.0M decrease
- Operating cash flow $215.0M, up from $206.3M; $655.4M Azstarys acquisition payment
- Cash $144.8M; $50.0M accelerated share repurchase and $300.0M acquisition financing draw
Risk Factors
- Newly added AI risk: internal and vendor AI use may expose confidential data or create inaccurate outputs, amid evolving U.S. and EU regulation
- Most materially updated competition risk: Hikma launched Nucynta IR and ER generics on February 25, 2026 and March 11, 2026
- Regulatory risk: FDA heightened promotional scrutiny in September 2025, increasing challenge risk for Xtampza ER advertising
- Operational risk: sole manufacturer Patheon supplies Xtampza ER and Nucynta ER, creating disruption exposure
- Financial risk: $854.5 million term loan plus $241.5 million convertible notes, with floating-rate debt unhedged
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other COLLEGIUM PHARMACEUTICAL, INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.